EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Preservative-free Unit-Dose Sodium Hyaluronate Eye Drops (0.3%) Obtained Approval from NMPA for Commercialisation in China

2024.09.13

Essex Bio-Technology Reports 1st H 2024 Net Profit of HK$157.4 Million Poised for Future Success Underpinned by Proven Product Base and Promising Pipeline of Products

2024.08.26

Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2024

2024.08.26

Date

Title

2018-07-24

Essex Bio-Technology Investing in Chengdu Shanggong Medical Technology Co.,Ltd., A Data Analytics Company for Diabetic Retinopathy Diagnosis

2018-07-18

Essex Bio-Technology Enters into Global Co-Development Agreement with Mitotech to Fund Phase 3 Clinical Trial in U.S. FDA of a First-In-Class Drug for Dry Eye Disease

2018-04-12

Zhuhai Essex Bio-Pharmaceutical Obtained a GMP Certificate for Preservative-Free Single-Dose Tobramycin Eye Drops

2018-04-10

Essex Bio-Technology appoints Dr. Xue Qi as Chief Scientific Officer for its R&D Centre in USA

2018-03-16

Group Profit Recorded Growth of 22.8% in 2017

2018-03-06

Change of Company Logo Represents a Transformation for Essex Bio-Technology Pioneering Global Regenerative Science & Technology

2018-02-26

Essex Bio-Technology announces investment in MeiraGTx, a biotech company developing novel gene therapy treatments

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT